ReviewFrontiers in surgery2025
Lower early-stage rectal cancer surgical approaches: therapeutic options and cancer biomarker alterations.
Review in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low early-stage rectal cancer (LeREC), typically referring to pTis and pT1 tumors without nodal involvement or lymphovascular/perineural invasion and confined to the mucosa, can potentially be treated with transanal local excision techniques. While transanal endoscopic microsurgery (TEM) remains a common minimally invasive option, it is technically demanding and costly. There remains a need for safer, simpler, and more accessible alternatives. Objective: To evaluate the safety and efficacy of a simplified transanal excision (sTE) combined with the Ruiyun procedure for hemorrhoids (RPH) compared to conventional TEM in the treatment of LeREC. Methods: In this randomized, controlled study, 48 patients with LeREC located within 12 cm of the anal verge were assigned to receive either TEM ( Results: All patients were followed up for 12 months. The sTE + RPH group showed reduced intraoperative bleeding, lower surgical costs, and fewer complications compared to the TEM group. Expression levels of CDK2/4/6, FOXD1, and PAK4 were observed to vary between groups and were potentially associated with recurrence risk. Conclusion: The combination of sTE and RPH may offer a safe, cost-effective, and feasible alternative to TEM for treating LeREC, particularly in resource-limited settings. It facilitates wider clinical application without compromising curative efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.